REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., listed under ticker TZAC, is the post-combination entity formed through Tenzing Acquisition Corp's merger with clinical-stage biopharmaceutical company Reviva Pharmaceuticals. Tenzing Acquisition Corp completed its initial public offering in 2020, targeting the healthcare and life sciences sector with a focus on central nervous system and neuropsychiatric drug development. The 10-Q quarterly report, filed with the SEC on January 14, 2021, under accession number 0001104659-21-004303, captures the company's financial position during the de-SPAC transition period. Reviva Pharmaceuticals is developing novel small-molecule therapeutics for CNS disorders. Sign up at SpacDesk for complete filing history, SPAC analytics, and real-time deal tracking on TZAC and the broader SPAC universe.